On the contrary, in Yabuta study, described below, the BRAF mutation was not a predictive factor in term of tumor behavior as in was present in 64%, 70%, and 80% of PTMC from the non-progressing group, size-increase group, and lymph node metastasis group, respectively (83). The gene discussed is BRAF; the disease is neoplasm.